JP2024541680A - Ｃｃｒ８抗原結合ユニット及びその使用 - Google Patents

Ｃｃｒ８抗原結合ユニット及びその使用 Download PDF

Info

Publication number
JP2024541680A
JP2024541680A JP2024533211A JP2024533211A JP2024541680A JP 2024541680 A JP2024541680 A JP 2024541680A JP 2024533211 A JP2024533211 A JP 2024533211A JP 2024533211 A JP2024533211 A JP 2024533211A JP 2024541680 A JP2024541680 A JP 2024541680A
Authority
JP
Japan
Prior art keywords
seq
nos
antigen
binding unit
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541680A5 (https=
Inventor
康立山
劉紅水
王茘娜
尹尚
李収
万兵
時文化
陳敏
戴薪伝
ベロヴィン、デイヴィッド
張静
Original Assignee
ザイ ラボ （シャンハイ） カンパニー、リミテッド．
ザイ ラボ （ユーエス） エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイ ラボ （シャンハイ） カンパニー、リミテッド．, ザイ ラボ （ユーエス） エルエルシー filed Critical ザイ ラボ （シャンハイ） カンパニー、リミテッド．
Publication of JP2024541680A publication Critical patent/JP2024541680A/ja
Publication of JP2024541680A5 publication Critical patent/JP2024541680A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024533211A 2021-12-02 2022-12-02 Ｃｃｒ８抗原結合ユニット及びその使用 Pending JP2024541680A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/134930 2021-12-02
CN2021134930 2021-12-02
PCT/CN2022/136276 WO2023098888A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Publications (2)

Publication Number Publication Date
JP2024541680A true JP2024541680A (ja) 2024-11-08
JP2024541680A5 JP2024541680A5 (https=) 2025-12-05

Family

ID=86611552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533211A Pending JP2024541680A (ja) 2021-12-02 2022-12-02 Ｃｃｒ８抗原結合ユニット及びその使用

Country Status (11)

Country Link
US (1) US20250034266A1 (https=)
EP (1) EP4441098A4 (https=)
JP (1) JP2024541680A (https=)
KR (1) KR20240112929A (https=)
CN (1) CN119072494A (https=)
AU (1) AU2022400921A1 (https=)
CA (1) CA3239784A1 (https=)
IL (1) IL313177A (https=)
MX (1) MX2024006743A (https=)
TW (1) TW202342533A (https=)
WO (1) WO2023098888A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2024240224A1 (zh) * 2023-05-23 2024-11-28 再鼎医药(上海)有限公司 包含抗ccr8抗体的制剂及其用途
JPWO2024248037A1 (https=) 2023-05-30 2024-12-05
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN120230205A (zh) * 2023-12-29 2025-07-01 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
AU2022400921A1 (en) 2024-06-27
CA3239784A1 (en) 2023-06-08
KR20240112929A (ko) 2024-07-19
EP4441098A4 (en) 2026-03-04
MX2024006743A (es) 2024-08-27
EP4441098A1 (en) 2024-10-09
TW202342533A (zh) 2023-11-01
WO2023098888A1 (en) 2023-06-08
US20250034266A1 (en) 2025-01-30
IL313177A (en) 2024-07-01
CN119072494A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
WO2023098888A1 (en) Ccr8 antigen binding unit and uses thereof
US11267885B2 (en) CD47 antigen binding unit and uses thereof
EP3356532B1 (en) Agonistic antibodies specifically binding human cd40 and methods of use
JP7789386B2 (ja) Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
ES2717908T3 (es) Anticuerpos S100A4 y usos terapéuticos de los mismos
JP2021517888A (ja) 抗クローディン１８．２抗体およびその使用
JP2020504095A (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
UA128035C2 (uk) Антитіло, що специфічно зв'язує pd-1, і спосіб його застосування
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
EP3404040B1 (en) Anti-myl9 antibody
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
TWI862019B (zh) 治療性ｃｄ２４人類化單株抗體及抗腫瘤轉譯應用
HK40120943A (zh) Ccr8抗原结合单元及其用途
RU2780859C2 (ru) Cd47-антигенсвязывающая единица и ее применение
US20240174741A1 (en) Il-38-specific antibodies
CA3000400C (en) Agonistic antibodies specifically binding human cd40 and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251127